Celerion https://validator.w3.org/feed/docs/rss2.html Drug-Drug Interaction (DDI) Clinical Protocol Development Tue Mar 20, 2012 Webinar: Challenges in Early Comparability Assessment of Biosimilars Tue Apr 24, 2012 Webinar: Discerning Early Clinical Signals of Efficacy for Treating Respiratory Diseases Celerion acquires early stage clinical research operations from MDS Pharma Services Celerion launches new Hybrid ECG Core Lab for Phase I clinics Celerion launches electronic laboratory notebook, achieving major milestone toward 100% paperless laboratories Celerion adds USP Clean Room, enabling efficient execution of microtracer and microdosing studies Celerion and BryanLGH Health System Form Alliance to Provide Dedicated Hospital Beds for Phase I Studies Celerion recognized as member of the UK Respiratory Therapeutic Capability Cluster Member of UK Respiratory Therapeutic Capability Cluster Celerion awarded prestigious LEED® Green Building Certification Celerion announces highly automated ECG analysis enabling data delivery within 37 days from first patient dosed Celerion receives ANVISA certification Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples Celerion receives license enabling Investigational Medicinal Products (IMPs) to be imported directly to their GMP-licensed facility Celerion appoints Dr. Raymond Farmen as Vice President of Global Bioanalytical Services Celerion scientist proud recipient of Scientific and Technological Achievement Award (STAA) from EPA Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality Celerion and Ricerca Biosciences announces “The Biosimilars Alliance” to offer clients a more effective development path for biosimilars Celerion announces expanded state-of-the-art ADME Suite in its Lincoln, Nebraska USA facility Celerion is the First CRO Headquartered in the USA to Receive Full Accreditation from AAHRPP Celerion Builds on Respiratory Capabilities With the Addition of an On-site Bronchoscopy Suite Types and Features of NDA Enabling Celerion appoints Dr. Bruce Morimoto as Executive Director, Applied Translational Medicine Celerion Expands Belfast Facility with Containment Room to Enable Live Biologics and Vaccine Studies Celerion Appoints Clayton Dehn as Executive Director, Metabolic Diseases Celerion Appoints John Horkulak as Executive Director, Eurasian Site Operations Celerion Celebrates 80 Years of Conducting Business at Global Headquarters in Lincoln, Nebraska Celerion Opens Operations in South Korea at Seoul National University Hospital Clinical Trial Center Celerion and Korean Drug Development Fund Form Collaboration to Strengthen Early Phase Clinical Research in South Korea Celerion Selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium for The Beta Cell Project Celerion Appoints Dr. Robert Lester as Chief Cardiologist, Global Medical Director of Cardiac Safety Services Celerion Expands Ophthalmological Capabilities to Patient Populations in Collaboration with Queen’s University, Belfast Celerion Announces Membership into the Cardiac Safety Research Consortium (CSRC) Celerion Completes Recapitalization Through Investment by MTS Capital Health Partners Celerion Expands its Cell-Based Assays Capabilities in Global Bioanalytical Services Assign Clinical Research Joins Celerion Celerion Recognized by Biopharmaceutical Clients as a Leader in Contract Research Quality Benchmarking Survey Supporting the Next Major Health Epidemic Newsletter: Q4 2016 Celerion Announces Celexus as a Premier Safety Reporting Tool for Phase I Clinical Trials Celerion Named Best Translational Clinical Pharmacology Company 2016 Newsletter: Q1 2017 Celerion Appoints Dr. Marc Hoffman as Chief Medical Officer Celerion Implements Biometric Fingerprint Technology and Marks Five-Year Anniversary with Verified Clinical Trials Newsletter: Q2 2017 Celerion Receives a 2017 CRO Leadership Award in Multiple Categories for Clinical Research Excellence Newsletter: Q3 2017 Home